Literature DB >> 18193212

Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore.

Shirley Kow Yin Kham1, Chin Kok Soh, Te Chih Liu, Yiong Huak Chan, Hany Ariffin, Poh Lin Tan, Allen Eng Juh Yeoh.   

Abstract

OBJECTIVE: The distribution of thiopurine methyltransferase (TPMT) activity in Asian populations has not been well documented. We studied the TPMT phenotype in three major Asian ethnic groups in Singapore, namely the Chinese (Ch), Malays (Mal) and Indians (Ind), with the aim of carrying out a comprehensive survey of the distribution of TPMT activity in Asians.
METHODS: A radiochemical assay was used to measure the enzymatic activity of TPMT in the red blood cells (RBCs) of 479 healthy adults (Ch=153, Mal=163 and Ind=163). Cut-off points for intermediate TPMT activity were validated using a receiver operating curve (ROC) analysis. PCR-based methods were used to screen for the TPMT*3C, TPMT*3A and TPMT*6 variants.
RESULTS: The histogram of the combined population cohort showed a bimodal distribution of TPMT activity, with no subject having low TPMT activity (<5 units). In total, TPMT variants were detected in 14 subjects (*1/*3C in 13 subjects; *1/*3A in one subject). We observed significant inter-ethnic differences in terms of TPMT activity (p<0.001), with the Malays showing a higher median activity than the Chinese or Indians (17.8 units vs 16.4 units). The Malays also showed a higher methylation rate--with a cut-off point for intermediate TPMT activity of 11.3 units--than the Chinese (9.9 units) or Indians (9.4 units). A high phenotype-genotype correlation of >97% was observed in all three races. We also genotyped 418 childhood leukaemias. The combined analysis of subjects participating in this and a previous study--1585 subjects--showed that 4.7% of Chinese (n=30/644), 4.4% of Malays (n=24/540) and 2.7% of Indians (n=11/401) were heterozygous at the TPMT gene locus.
CONCLUSION: This is the first comprehensive TPMT phenotype and genotype study in Asian populations, particularly in the Malays and Indians.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18193212     DOI: 10.1007/s00228-007-0426-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  36 in total

Review 1.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms.

Authors:  D Otterness; C Szumlanski; L Lennard; B Klemetsdal; J Aarbakke; J O Park-Hah; H Iven; K Schmiegelow; E Branum; J O'Brien; R Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  1997-07       Impact factor: 6.875

3.  Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations.

Authors:  Jan-Gowth Chang; Long-Shyong Lee; Chih-Mei Chen; Mu-Chin Shih; Mei-Chen Wu; Fuu-Jen Tsai; Der-Cheng Liang
Journal:  Pharmacogenetics       Date:  2002-04

4.  Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics.

Authors:  Oreste E Salavaggione; Liewei Wang; Mathieu Wiepert; Vivien C Yee; Richard M Weinshilboum
Journal:  Pharmacogenet Genomics       Date:  2005-11       Impact factor: 2.089

5.  Erythrocyte thiopurine methyltransferase activity in a Korean population.

Authors:  I J Jang; S G Shin; K H Lee; D S Yim; M S Lee; H H Koo; H K Kim; D R Sohn
Journal:  Br J Clin Pharmacol       Date:  1996-11       Impact factor: 4.335

6.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.

Authors:  H L Tai; E Y Krynetski; C R Yates; T Loennechen; M Y Fessing; N F Krynetskaia; W E Evans
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

7.  Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties.

Authors:  R M Weinshilboum; F A Raymond; P A Pazmiño
Journal:  Clin Chim Acta       Date:  1978-05-02       Impact factor: 3.786

8.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

Review 9.  Drug methylation in cancer therapy: lessons from the TPMT polymorphism.

Authors:  Eugene Krynetski; William E Evans
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

10.  Azathioprine in rheumatoid arthritis.

Authors:  M Mason; H L Currey; C G Barnes; J F Dunne; B L Hazleman; I D Strickland
Journal:  Br Med J       Date:  1969-02-15
View more
  15 in total

1.  NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity.

Authors:  Takaya Moriyama; Rina Nishii; Virginia Perez-Andreu; Wenjian Yang; Federico Antillon Klussmann; Xujie Zhao; Ting-Nien Lin; Keito Hoshitsuki; Jacob Nersting; Kentaro Kihira; Ute Hofmann; Yoshihiro Komada; Motohiro Kato; Robert McCorkle; Lie Li; Katsuyoshi Koh; Cesar Rolando Najera; Shirley Kow-Yin Kham; Tomoya Isobe; Zhiwei Chen; Edwynn Kean-Hui Chiew; Deepa Bhojwani; Cynthia Jeffries; Yan Lu; Matthias Schwab; Hiroto Inaba; Ching-Hon Pui; Mary V Relling; Atsushi Manabe; Hiroki Hori; Kjeld Schmiegelow; Allen E J Yeoh; William E Evans; Jun J Yang
Journal:  Nat Genet       Date:  2016-02-15       Impact factor: 38.330

2.  Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia.

Authors:  Patchva Dorababu; Narayana Nagesh; Vijay Gandhi Linga; Sadashivudu Gundeti; Vijay Kumar Kutala; Pallu Reddanna; Raghunadharao Digumarti
Journal:  Eur J Clin Pharmacol       Date:  2011-10-19       Impact factor: 2.953

3.  Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.

Authors:  Jun J Yang; Wendy Landier; Wenjian Yang; Chengcheng Liu; Lindsey Hageman; Cheng Cheng; Deqing Pei; Yanjun Chen; Kristine R Crews; Nancy Kornegay; F Lennie Wong; William E Evans; Ching-Hon Pui; Smita Bhatia; Mary V Relling
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

4.  TPMT*26 (208F-->L), a novel mutation detected in a Chinese.

Authors:  Shirley Kow Yin Kham; Chin Kok Soh; Derrick Chen Wee Aw; Allen Eng Juh Yeoh
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

5.  Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine.

Authors:  Salamun Desire; Poonkuzhali Balasubramanian; Ashish Bajel; Biju George; Auro Viswabandya; Vikram Mathews; Alok Srivastava; Mammen Chandy
Journal:  Med Oncol       Date:  2009-10-15       Impact factor: 3.064

6.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

7.  Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain.

Authors:  David Gurwitz; Cristina Rodríguez-Antona; Katherine Payne; William Newman; Javier P Gisbert; Emma Gutiérrez de Mesa; Dolores Ibarreta
Journal:  Eur J Hum Genet       Date:  2009-02-18       Impact factor: 4.246

8.  Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review.

Authors:  Lilla M Roy; Richard M Zur; Elizabeth Uleryk; Chris Carew; Shinya Ito; Wendy J Ungar
Journal:  Pharmacogenomics       Date:  2016-03-29       Impact factor: 2.533

Review 9.  Thiopurine S-methyltransferase testing for averting drug toxicity: a meta-analysis of diagnostic test accuracy.

Authors:  R M Zur; L M Roy; S Ito; J Beyene; C Carew; W J Ungar
Journal:  Pharmacogenomics J       Date:  2016-05-24       Impact factor: 3.550

Review 10.  Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.

Authors:  Ji Young Chang; Jae Hee Cheon
Journal:  Dig Dis Sci       Date:  2019-07-09       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.